Clinical Trial Modernization Act
- Sponsor
- Rep. Ruiz, Raul [D-CA-25]
- Committees
- Ways and Means Committee (primary)
- Last action
- May 20, 2025
Bottom line
The bill seeks to diversify clinical trial demographics by removing financial and logistical barriers for underrepresented populations through grants, legal protections for participant support, and a limited tax exemption.
What it actually does
This bill aims to increase the participation of underrepresented populations in clinical trials by authorizing grants for community education and recruitment, amending federal anti-fraud statutes to exempt certain participant expenses and cost-sharing payments, and creating a limited tax exclusion for remuneration received by trial participants. It seeks to remove financial and logistical barriers that currently hinder diverse representation in medical research.
Proponents argue
Supporters argue that the bill addresses critical disparities in clinical trial participation, which currently limit the generalizability of research findings and exacerbate health inequities. By removing financial disincentives and actively engaging communities, the bill will lead to more inclusive and effective medical advancements, particularly for diseases disproportionately affecting underrepresented groups.
Opponents contend
Critics might argue that while the intent is good, the bill could open avenues for undue influence or create incentives that compromise the integrity of clinical trial participation, even with safeguards. Concerns could also be raised about the potential for increased costs to federal healthcare programs or the administrative burden of implementing new grant programs and monitoring compliance with the new exemptions.
The bill is relatively short and its core provisions are clearly stated, making it accessible for a quick but thorough review.
Section 2
Definition of "Underrepresented Population"
This section defines "underrepresented population" for the purposes of the Act. It explicitly adopts the definition used by the National Institutes of Health (NIH) in its Toolkit for Patient-Focused Therapy Development (published April 1, 2024) and also includes populations recognized by the Food and Drug Administration (FDA). This ensures a broad and consistent understanding of the target demographic for the bill's initiatives.
Supporters argue
Supporters argue that a clear and consistent definition is crucial for targeting resources effectively and ensuring that the bill's benefits reach the intended communities, thereby addressing historical inequities in clinical trial participation.
Critics contend
No specific opposition is typically raised against definitional provisions unless the definition itself is seen as overly broad or too narrow, which is not immediately apparent here.
Tradeoffs
The main tension is ensuring the definition is comprehensive enough to capture all deserving groups without being so vague as to dilute the focus.
Section 3
Grants to Encourage Clinical Trial Enrollment by Underrepresented Populations
This section authorizes the Secretary (likely of Health and Human Services) to issue grants and contracts to support community education, outreach, and recruitment for clinical trials. The focus is on trials for devices and drugs (including vaccines) that address diseases disproportionately affecting underrepresented populations. Activities can include working with community sites, training healthcare personnel (especially from underrepresented groups), engaging community stakeholders, and fostering partnerships with community-based organizations. Priority is given to entities developing multi-language materials or working in traditionally underrepresented areas like tribal communities.
Section 4
Exemptions for Participant Expenses and Digital Health Technologies from Anti-Kickback Statute
This section amends the Social Security Act to clarify that certain remuneration to clinical trial participants is not considered illegal kickbacks or inducements. Specifically, it exempts payments for expenses incurred during a trial (like travel, transportation, and meals), provided these are available to all participants and facilitate inclusion of diverse populations. It also exempts the free provision of digital health technologies if they facilitate participation of underrepresented patient populations and are necessary for trial involvement. This aims to remove legal ambiguities that might deter sponsors from covering these costs.
Section 5
Exemption for Clinical Trial Cost-Sharing Payments from Anti-Kickback and False Claims Laws
This section specifies that payments made by drug or device manufacturers (or their agents) for patient cost-sharing obligations associated with clinical trial participation will not be considered violations of the Civil Monetary Penalties Law, the Anti-Kickback Statute, or the False Claims Act, provided certain conditions are met. These conditions include consistency with federal healthcare program coverage rules, reasonableness for facilitating enrollment of underrepresented subjects or reducing attrition, availability throughout the trial, non-contingency on future product use, not exceeding patient obligations, and agreement not to accept other financial assistance. It also requires safeguards like no advertising of subsidies, informed consent, written agreements with investigators, and capped enrollment.
Section 6
Exclusion from Gross Income for Clinical Trial Remuneration
This section amends the Internal Revenue Code of 1986 to exclude from an individual's gross income the value of any payment received for participation in an approved clinical trial. This exclusion is capped at $2,000 per taxable year. This means participants would not have to pay income tax on these payments, up to the specified limit.
The specific wording "other than patient cost-sharing obligations" in the remuneration exemption for expenses.
Section 4(a)(i) and 4(b)(M)
Why it matters:Standard legislative drafting to precisely define the scope of an exemption and avoid overlap with other provisions (like Section 5, which specifically addresses cost-sharing).
Case for: Ensures clarity and prevents double-counting or confusion with the separate, more detailed provisions regarding cost-sharing payments.
Case against: No strong case against, as it's a clarifying exclusion.
Estimated impact: Clarifies the scope of exemptions, preventing potential legal ambiguities for sponsors and participants.
The condition that payment of patient cost-sharing obligations must be a "reasonable means of facilitating enrollment of an underrepresented set of subjects or reducing the likelihood of attrition."
Section 5, paragraph (2)
Why it matters:This clause introduces a critical programmatic justification for the cost-sharing payments, linking them directly to the bill's core goal of increasing underrepresented participation and retention.
Case for: Ensures that the cost-sharing payments are genuinely aligned with the bill's purpose and not just a general subsidy, thus preventing potential abuse.
Case against: Could be seen as introducing a subjective standard that might be difficult to prove or disprove, potentially leading to disputes or inconsistent application.
Estimated impact: Directs the application of cost-sharing support towards the bill's diversity goals, rather than general financial assistance.